19 terminated. 19 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 19 | Terminated 19 |
Follow Neurodevelopmental Disorders: new trials by email Literature Review of Neurodevelopmental Disorders trials Research Report on Neurodevelopmental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children Adhansia XR - Attention Deficit/Hyperactivity Disorder | Phase 4 | Terminated | Purdue Pharma LP | 103 | 2021-08-03 | 2023-08-22 |
| Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) Adhansia XR, Concerta - Attention-Deficit/Hyperactivity Disorder | Phase 4 | Terminated | Purdue Pharma LP | 267 | 2020-07-30 | 2023-07-27 |
| A Study of Glutathione in Children With Autism Spectrum Disorder Glutathione - Autism Spectrum Disorder | Phase 4 | Terminated | University of Chicago | 6 | 2019-07-01 | 2025-09-18 |
| Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder Aripiprazole, Placebo - Tourette's Disorder (TD) | Phase 4 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 36 | 2018-10-13 | 2021-03-09 |
| Neurophysiological Markers of Pediatric Irritability and Its Response to Intervention CNS Stimulant - ADHD | Phase 4 | Terminated | Milton S. Hershey Medical Center | 11 | 2018-06-01 | 2025-08-26 |
| Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Methylphenidate, Risperidone - Attention Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder | Phase 4 | Terminated | Sheba Medical Center | 5 | 2017-02-01 | 2020-03-18 |
| Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD Immediate Release Methylphenidate, Placebo - Attention Deficit Disorder With Hyperactivity, Behavioral Insomnia of Childhood | Phase 4 | Terminated | Milton S. Hershey Medical Center | 3 | 2016-01-01 | 2019-09-17 |
| Lisdexamfetamine's Effect In ADHD in the Brain and Cognition Lisdexamfetamine - Attention Deficit Hyperactivity Disorder | Phase 4 | Terminated | University of California, Davis | 6 | 2014-02-01 | 2019-12-26 |
| A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder Naltrexone, Placebo - ADHD, Attention Deficit Hyperactivity Disorder | Phase 4 | Terminated | Massachusetts General Hospital | 3 | 2012-11-01 | 2016-05-27 |
| A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents Atomoxetine, Osmotic-release oral system methylphenidate, Placebo - Attention Deficit Hyperactivity Disorder | Phase 4 | Terminated | Eli Lilly and Company | 23 | 2010-06-01 | 2012-11-28 |
| Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia Guanfacine extended-release tablets, Placebo comparator - Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder | Phase 4 | Terminated | Children's Specialized Hospital | 29 | 2010-06-01 | 2014-08-11 |
| Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum Disorders Natrol - Sleep Disorder | Phase 4 | Terminated | University of Nebraska | 1 | 2010-03-04 | 2023-09-08 |
| Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity Lis-dexamphetamine - Attention Deficit Hyperactivity Disorder, Glucose Intolerance | Phase 4 | Terminated | Duke University | 14 | 2009-12-01 | 2014-02-20 |
| Omega-3 Fatty Acids as an Adjunctive Therapy for Stimulants in Children With ADHD Stimulants plus Lovaza, Stimulants plus placebo - Attention Deficit Hyperactivity Disorder | Phase 4 | Terminated | Antonios Likourezos | 15 | 2009-12-01 | 2023-12-14 |
| Chantix in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD) Varenicline (Chantix) - Attention Deficit/Hyperactivity Disorder, Smoking Cessation | Phase 4 | Terminated | Massachusetts General Hospital | 2 | 2009-04-01 | 2017-10-20 |
| Adherence to Stimulant Treatment in Attention-Deficit Hyperactivity Disorder (ADHD) Patients (ASTA) Immediate release methylphenidate (Medikinet®), Extended release methylphenidate (Medikinet retard®) - ADHD | Phase 4 | Terminated | Prof. Huss | 32 | 2009-03-01 | 2014-05-07 |
| Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE Atomoxetine - Attention Deficit Hyperactivity Disorder, Cannabis Abuse | Phase 4 | Terminated | Eli Lilly and Company | 7 | 2008-09-01 | 2010-08-24 |
| Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL Atomoxetine - Attention Deficit Hyperactivity Disorder | Phase 4 | Terminated | Monarch Medical Research | 1 | 2006-06-01 | 2012-04-26 |
| Safety Study of Galantamine in Tic Disorders galantamine - Tourette's Syndrome, Motor Tic Disorder | Phase 4 | Terminated | Parkinson's Disease and Movement Disorders Center | 1 | 2005-09-01 | 2009-08-25 |
Attention Deficit Disorder with Hyperactivity (15) · Autism Spectrum Disorder (2) · Sleep Wake Disorders (2) · Tourette Syndrome (2) · Aggression (1) · Autistic Disorder (1) · Conduct Disorder (1) · Glucose Intolerance (1) · Marijuana Abuse (1) · Obesity (1) · Oppositional Defiant Disorder (1) · Parasomnias (1) · Sleep Initiation and Maintenance Disorders (1) · Smoking (1) · Smoking Cessation (1)
Mental Disorders (19) · Attention Deficit and Disruptive Behavior Disorders (15) · Nervous System Diseases (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Neurologic Manifestations (3) · Basal Ganglia Diseases (2) · Behavior (2) · Brain Diseases (2) · Central Nervous System Diseases (2) · Child Development Disorders, Pervasive (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Heredodegenerative Disorders, Nervous System (2)
Atomoxetine Hydrochloride (3) · Central Nervous System Stimulants (2) · Lisdexamfetamine Dimesylate (2) · Methylphenidate (2) · Sugars (2) · Aripiprazole (1) · Galantamine (1) · Glutathione (1) · Guanfacine (1) · Naltrexone (1) · Omacor (1) · Risperidone (1) · Varenicline (1)
Eli Lilly and Company (2) · Massachusetts General Hospital (2) · Milton S. Hershey Medical Center (2) · Purdue Pharma LP (2) · Antonios Likourezos (1) · Children's Specialized Hospital (1) · Duke University (1) · Monarch Medical Research (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Parkinson's Disease and Movement Disorders Center (1) · Prof. Huss (1) · Sheba Medical Center (1) · University of California, Davis (1) · University of Chicago (1) · University of Nebraska (1)
United States (14) · Netherlands (2) · Canada (1) · Germany (1) · Hungary (1) · Israel (1) · Spain (1) · Sweden (1)
Donald S Higgins, M.D. (1) · Donald W Lewis, MD (1) · Doron Gothelf, professor (1) · Eva Kohegyi, MD, MS (1) · Howard Needelman, MD (1) · Juan D Pedraza, MD (1) · Julie B Schweitzer, PhD (1) · Karam Radwan, MD (1) · Kathleen Malloy, MD (1) · Michael Huss, Prof. Dr. (1) · Raman Baweja, M.D., M.S. (1) · Raman Baweja, MD, MS (1) · Scott H Kollins, PhD (1) · Thomas A Rugino, MD (1)
2009 (1), 2018 (1)